Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
BenevolentAI

BenevolentAI

A bioinformatics startup company that develops and applies artificial intelligence and machine learning technology to analyze scientific data in order to create human health and bioscience applications.

Overview

BenevolentAI combines AI and machine learning with science to decipher complex disease biology, generate novel insights and discover more effective medicines. Its computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programs from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organizations, BenevolentAI is the only AI-drug discovery company with a clinically validated approach, having discovered a leading repurposed drug candidate for COVID-19.

BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.

Ken Mulvany, Brent Gutekunst, Ivan Griffin and Michael Brennan founded Stratified Medicine in November 13, 2013 in London, United Kingdom. The company changed its name to BenevolentAI in Sepetember 2016. It has offices in Cambridge, Belgium and New York.

Timeline

April 8, 2021
Data From Eli Lilly’s COV-BARRIER Trial Shows Baricitinib Reduced Deaths In Hospitalised COVID-19 Patients By 38%
February 11, 2021
BenevolentAI announces dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis.
January 27, 2021
BenevolentAI And AstraZeneca Achieve Collaboration Milestone With Novel AI-Generated Chronic Kidney Disease Target
November 20, 2020
FDA Grants Emergency Use Authorisation For Baricitinib In Hospitalised COVID-19 Patients Nine Months After Initial Hypothesis Was Published By BenevolentAI
April 10, 2020
Potential Treatment For COVID-19 Identified By BenevolentAI Enters Randomised Clinical Trial
September 17, 2019
BenevolentAI raises a $90,000,000 venture round from Temasek Holdings.
April 29, 2019
AstraZeneca Starts Artificial Intelligence Collaboration To Accelerate Drug Discovery
May 1, 2018
BenevolentAI Makes Joanna Shields New CEO
August 2015
BenevolentAI raises a $87,000,000 seed round from Lansdowne Partners, Lundbeck, Upsher-Smith Laboratories and Woodford Investment Management.
2013
BenevolentAI was founded by Brent Gutekunst, Ivan Griffin, Ken Mulvany and Michael Brennan.

Funding rounds

Patents

Further Resources

Title
Author
Link
Type
Date

#GBMDay: An AI-Enabled Approach to GBM Drug Discovery

Web

July 29, 2021

AI Uncovers a Potential Treatment for Covid-19 Patients

Tom Simonite

Web

April 17, 2020

AI: The Next Revolution In Medicine?

Web

January 23, 2019

AstraZeneca scores new goal on the pipeline front, adding its first AI-generated target to the portfolio

Max Gelman

Web

January 27, 2021

BenevolentAI & AstraZeneca: Fusing AI and Drug Discovery Expertise to Find New Treatments for CKD

Web

April 8, 2021

News

Title
Author
Date
Publisher
Description
BenevolentAI
April 8, 2021
www.prnewswire.com:443
The latest data published in Eli Lilly's Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to...
BenevolentAI
February 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient...
Conor Hale
January 27, 2021
FierceBiotech
After launching a collaboration nearly two years ago to bring artificial intelligence to kidney drug design, AstraZeneca and BenevolentAI believe they've discovered a winner.
BenevolentAI
January 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- BenevolentAI today announced that the biopharmaceutical company AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance...
Chris Stokel Walker
January 25, 2021
Business Insider
Because of her work, Insider named Joanna Shields, CEO of BenevolentAI, to our annual list of the 10 leaders transforming healthcare in Europe.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.